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Critical role for glycosphingolipids in Niemann-Pick
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Niemann-Pick type C (NPC) disease is a cholesterol Results and discussion
Niemann-Pick type C disease is widely viewed as a disor-lipidosis caused by mutations in NPC1 and NPC2
gene loci [1]. Most human cases are caused by der of cholesterol transport and homeostasis [2, 3, 15–18],
but substantial evidence also exists for significant involve-defects in NPC1 [2], as are the spontaneously
occurring NPC diseases in mice [3] and cats [4]. NPC1 ment of GM2 and GM3 gangliosides and other GSLs
[8–11]. In order to evaluate the contribution of GSLs toprotein possesses a sterol-sensing domain [1–3]
and has been localized to vesicles that are believed NPC pathogenesis, we treated NPC-affected mice and
cats with an inhibitor of glucosylceramide synthase, theto facilitate the recycling of unesterified
cholesterol from late endosomes/lysosomes to the enzyme responsible for the conversion of glucosylcera-
mide to lactosylceramide, a critical early step in the syn-ER and Golgi [1, 5–7]. In addition to accumulating
cholesterol, NPC1-deficient cells also accumulate thesis of gangliosides. We provided NB-DNJ [13, 14]
mixed in ground chow to mice (1200 mg/kg/day, begin-gangliosides and other glycosphingolipids (GSLs),
and neuropathological abnormalities in NPC disease ning at 3.5 weeks of age) and by direct oral administration
twice daily to cats (as given below). An assessment of theclosely resemble those seen in primary
gangliosidoses [1, 8–12]. These findings led us to clinical phenotype of mice with NPC (n  11) versus
wild-type littermates (n  9) revealed that in the earlyhypothesize that NPC1 may also function in GSL
homeostasis [9]. To evaluate this possibility, we stages of the disease, up to 49 days of age, NPC mice did
not display evidence of neurological dysfunction and weretreated murine and feline NPC models with
N-butyldeoxynojirimycin (NB-DNJ), an inhibitor of indistinguishable from wild-type littermates (Figure 1a).
However, between 50 and 62 days of age, 78% of un-glucosylceramide synthase, a pivotal enzyme in the
early GSL synthetic pathway [13, 14]. Treated animals treated NPC mice (n  9) could be classified as having
a clinical phenotype consisting of abnormal head and bodyshowed delayed onset of neurological dysfunction,
increased average life span (in mice), and reduced tremors on movement (tremors of intention) and a pro-
nounced ataxic gait. In contrast, we found that only 11%ganglioside accumulation and accompanying
neuropathological changes. These results are of NPC mice receiving NB-DNJ (n  9) displayed this
clinical phenotype at this age (Figure 1a). Between 63consistent with our hypothesis and with GSLs
being centrally involved in the pathogenesis of NPC and 75 days of age, all of the untreated mice (100%)
displayed tremors and ataxia, with none living past thisdisease, and they suggest that drugs inhibiting GSL
synthesis could have a similar ameliorating effect time period, whereas only 56% of the treated NPC mice
displayed abnormal motor function during this same pe-on the human disorder.
riod (Figure 1a,c). We continued to follow a group of
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Figure 1
NB-DNJ treatment in NPC mice and cats was found to delay the onset dish. In contrast, a 2-week-younger, untreated NPC mouse (9 weeks,
of clinical neurological disease, to increase longevity (murine NPC), and 5 days old) is unable to maintain a stable feeding position, falls to the
to reduce cellular pathology in the cerebellum. (a) The majority of right, and then lurches to the left (lower panels). (d) NB-DNJ treatment
untreated NPC mice showed a well-defined clinical phenotype also reduced the characteristic cerebellar pathology that occurs in
(ataxia and intention tremor) between 50 and 62 days of age; by NPC disease. The cerebellar cortex from normal mice shows typical
63–75 days of age, clinical neurological disease and lethality were distribution of Purkinje cells and layering when it is stained with
observed in all untreated NPC mice (open bars). In contrast, far fewer antibodies to Parvalbumin (upper left panel) and Calbindin (lower left
NB-DNJ-treated mice showed the clinical phenotype, and all were panel). Untreated NPC mice (upper middle panel) display numerous,
viable within this time frame (solid bars). NPC mice treated with NB- Parvalbumin-positive axonal spheroids of varying sizes in the granule
DNJ lived to 76–105 days of age, with many of them developing layer (arrowheads) and regions in which all Calbindin-positive Purkinje
the clinical phenotype during this period. (b) An evaluation of longevity cells have disappeared (lower middle panel). Parvalbumin staining in
in NB-DNJ-treated versus untreated NPC mice showed that treated treated NPC mice revealed Purkinje cell axons in the granule cell
animals lived to 89  5 days (average  SEM) (solid bar) versus layer that were mostly devoid of spheroids (upper right panel) and the
untreated mice, which lived to 67  1 day (open bar). (c) Time presence of numerous surviving Calbindin-labeled Purkinje cells
lapse photographs of an 11-week, 5-day-old NPC mouse treated with (lower right panel). The scale bar (lower right panel) represents 15
NB-DNJ (upper panels) reveals a normally functioning motor system m (applies to all).
since the animal maintains itself in a stable position on its feeding
motor system dysfunction during its treatment period, Neuropathological changes in NPC disease closely resem-
ble those observed in primary ganglioside storage diseasesand the older animal failed to develop ataxia. The four
normal cats treated with NB-DNJ (for 19, 23, 54, and 144 [9, 12, 19]; such changes include the presence of ectopic
dendrites on cortical pyramidal neurons and axonal spher-days, respectively) generally weighed less at the end of
the treatment period than age-matched, untreated, normal oids on cerebellar Purkinje cells and other GABAergic
neurons. The cerebellum is severely impacted in bothcats but otherwise appeared healthy. NB-DNJ not only
delayed the onset and/or progression of clinical deteriora- the mouse and cat models of NPC and likely gives rise
to a significant portion of the clinical phenotype in thesetion in mice and cats but also extended the life span of
mice (n  10) from 67  1 day (untreated) to 89  5 models as well as in human disease [9, 12]. To evaluate the
effectiveness ofNB-DNJ therapy on cerebellar pathology,days (treated), representing a 25% increase in longevity
(Figure 1b). we used antibodies to Parvalbumin and Calbindin, respec-
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Figure 2tively, to evaluate axonal spheroid formation and Purkinje
cell loss. In wild-type mice and cats, Parvalbumin-immu-
noreactivity was detected in Purkinje cells and in the
molecular layer, while Calbindin staining was observed
in Purkinje cells and their dendrites (Figure 1d). In feline
NPC disease, we previously found that axonal spheroids
initially appeared within the neuropil of deep cerebellar
nuclei and adjacent white matter and later spread proxi-
mally toward Purkinje cell somata prior to the death of
these neurons [12]. Purkinje cell axonal spheroids and
death correlate with worsening motor system dysfunction
in both the cat and mouse models [12, 19]. Consistent
with these earlier studies, untreated 9- to 10-week-old
NPC mice in the present study displayed an extensive
number of Parvalbumin-positive axonal spheroids (Figure
1d). In contrast, NB-DNJ-treated NPC mice at this same
age showed diminished spheroid formation in the granule
cell layer and preserved Purkinje cell architecture to vary-
ing degrees throughout the extent of cerebellar folia. Cal-
bindin staining of untreated NPC mice revealed a nearly
complete absence of Purkinje cells in many areas of the
cerebellum,whileNPCmice treatedwithNB-DNJ exhib-
ited persistence of many of these neurons (Figure 1d).
To assess the effectiveness ofNB-DNJ in reducing gangli-
oside storage in NPC brain, we performed high-perfor-
mance, thin-layer chromatography (HPTLC) [20] and
ganglioside immunocytochemistry [9]. HPTLC analysis
of NPC-affected brains confirmed GM3 and GM2 gangli-
oside accumulation in the cerebral cortex of mice and cats
with NPC (Figure 2a). NB-DNJ treatment resulted in a
diminution in ganglioside levels, with notable decreases
NB-DNJ treatment diminishes ganglioside storage in the brains ofof GM3 and GM2 gangliosides in the cerebral cortex of
murine and feline NPC-affected animals. (a) HPTLC analysis of brainboth models of NPC (Figure 2a). Semiquantitative analy-
gangliosides in cats (lanes 1–4) and mice (lanes 5–9) with and withoutsis of the plates revealed that in feline and murine NPC,
NB-DNJ treatment. The standards (stds) lane shows the location of
respectively, GM3 was reduced from 5.3% to 3.0% and GM3 and GM2 gangliosides (upper and lower spots, respectively).
from 6.3% to 4.0% of total lipid bound sialic acid, while Untreated and treated 33-week-old wild-type cats (lanes 1 and 4,
respectively), and 9.5-week-old mice (lanes 5 and 9, respectively)GM2 levels were reduced from 2.7% to 1.1% and from
exhibit little or no GM3 and GM2 gangliosides, whereas age-4.2% to 2.2% of total lipid bound sialic acid. Previous
matched, untreated cats and mice with NPC (lanes 2 and 6,
studies in which we used immunocytochemical staining respectively) show increased levels of both of these gangliosides.
to localize GM2 ganglioside in NPC disease revealed that In comparison, the 33-week-old NPC cat treated with NB-DNJ for 54
days (lane 3) and the two 9.5-week-old NPC mice treated for 6this ganglioside was elevated in neurons of the cerebral
weeks (lanes 7 and 8) exhibited reduced levels of both GM3 andcortex, cerebellum, and other brain regions [9]. For the
GM2 gangliosides. (b–e) Representative examples of (b,d) cerebralpresent study, wemade a similar analysis in treated versus cortex and (c,e) cerebellum immunostained for GM2 ganglioside in
untreated NPC mice (Figure 2b,c) and cats (Figure 2d,e) NPC (b,c) mice and (d,e) cats with and without NB-DNJ treatment.
Tissues are from the same animals used in the HPTLC studies.to determine if NB-DNJ treatment reduced ganglioside
Untreated NPC mice and cats display GM2 accumulation instorage in these populations of neurons. We found that
pyramidal neurons of the cerebral cortex and in Purkinje and granuletreatment caused a visible reduction in storage material
cells of the cerebellum. Tissues from animals treated with NB-DNJ
within individual neurons of the cerebral cortex (Figure show reduced levels of GM2 immunoreactivity. The scale bar in the
2b,d) and cerebellum (Figure 2c,e) in most sections ana- lower right panel represents 100 m for (d), 10 m for (e), and 42
m for (b) and (c).lyzed. In the cerebral cortex, GM2 immunoreactivity was
most conspicuously diminished in pyramidal neurons,
while in the cerebellum, GM2 was predominantly re-
rological disease in murine and feline NPC underscoresduced in granule cells (mouse, cat) and in Purkinje cells
the importance of glycosphingolipid metabolism and stor-(mouse).
age in the NPC disease cascade and suggests that the
inhibition of glycosphingolipid synthesis represents anOur demonstration thatNB-DNJ ameliorates clinical neu-
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effective approach toward therapy for this disorder. Inter- unrelated to its effect on GLS synthesis, a similar result
stemming from the use of a related but more specificestingly, similar approaches directed at lowering choles-
terol in NPC disease were reported to have no significant glucosylceramide synthase inhibitor, N-butyl-deoxygalac-
tonojirimycin, or NB-DGJ (14), on NPC mice (Gondre´-impact on clinical neurological progression [21, 22]. NB-
DNJ therapy has also recently been shown to effectively Lewis and S.U.W., unpublished data) supports the role
for GSLs. Our results are consistent with the view thatreduce levels ofGM1 ganglioside in circulating leukocytes
in humanGaucher disease [23] as well as GM2 ganglioside NPC1 is in some manner linked to ganglioside trafficking
or synthesis and that GSLs are centrally involved in thelevels and cytopathology in murine Tay-Sachs and Sand-
hoff diseases [24, 25]. Substrate deprivation has also been NPC pathogenic cascade. Successful amelioration of NPC
disease in murine and feline models also suggests thatachieved genetically by a cross of Sandhoff disease mice
(in which GM2 ganglioside accumulation occurs second- inhibitors of GSL synthesis may be useful in the clinical
management of human NPC disease.arily to a deficiency in lysosomal -hexosaminidase) with
another line of mice in which the gene for 1,4-N-acetyl-
galactosaminyltransferase (GalNAcT, or GM2 synthase) Materials and methods
had been ablated [26]. The latter mice lack the ability to Reagents and models
produce GM2 and higher-order complex gangliosides. NB-DNJ (OGT 918; Vevesca) was generously provided by Oxford Glyco-
Sciences. Anti-GM2 ganglioside antibody (1:2,000) was kindly providedThe double mutant animals, in comparison to the mice
by P. Livingston (Memorial Sloan Kettering Medical Center, New York).with Sandhoff disease alone, exhibited significantly less
Anti-Parvalbumin antibody (1:5,000 and 1:10,000 on cortical and cere-intracellular storage, improved neurological function, and bellar sections, respectively) and anti-Calbindin antibody (1:500) were
increased longevity. The above findings indicate that sub- purchased from Sigma (St. Louis, Missouri, USA). The BALBc/NPCnih
mice [11] used to establish a breeding colony were obtained from Dr.strate deprivation is an effective therapeutic approach to
Peter Pentchev at the NIH (Bethesda, Maryland, USA), while cats withreducing ganglioside accumulation in a number of storage
NPC [28] were from a colony of animals maintained at Colorado Statedisorders. Recently, NPC mice have also been subject to University. For phenotype assessment, mice were evaluated based on
substrate deprivation through a similar genetic cross with the presence or absence of standardized clinical features: The presence
of both an ataxic gait and an intention tremor was scored as displayingGalNAcT knockout mice [27]. The double homozygous
a clinical phenotype. Two separate trials in mice were done. The firstmutants, as anticipated, did not display any detectable
was not blinded; the second trial was blinded and supported the resultsaccumulation of GM2 or other complex gangliosides but
of the first trial. An assessment of the neurological states of the cats
rather possessed higher-than-normal levels of GM3 and utilized standard postural, reflex, and cranial nerve evaluations performed
GD3 gangliosides. Interestingly, neurons in these animals by a veterinary neurologist lacking knowledge of the treatment status of
the animals. Procedures for which animals were used were performedwere reported to lack evidence for an accumulation of
in accordance with the recommendations and approval of the Institutionalunesterified cholesterol, a finding consistent with the pos-
Animal Care Use Committees of the Albert Einstein College of Medicine
sibility that cholesterol storage in NPC neurons occurs and Colorado State University.
secondarily to the accumulation of GM2 or higher-order
glycosphingolipids. In contrast to the Sandhoff-GalNAcT HPTLC and Immunocytochemistry
double knockouts, clinical disease in the NPC-GalNAcT For HPTLC studies, frozen tissue was homogenized, and total lipids
were obtained by standard Folch extraction. A volume of total lipid extractdouble mutants did not improve; these results suggest
equivalent to 10 mg wet weight was base partitioned via publishedthat the storage of higher-order gangliosides and choles-
methods [20]. The upper phase was purified by SEP PAK C18 chromatog-terol are not essential for the generation of brain dysfunc- raphy, dried under N2, and resuspended, and the extract was separatedtion. Notably, it has been previously shown by HPTLC on HPTLC plates. Total lipid bound sialic acids (which include ganglio-
analysis that neutral glycolipids in the early glycosphingo- sides) were imaged with resorcinol and identified by comparison with
purified ganglioside standards. Developed HPTLC plates were scannedlipid pathway (glucosylceramide and lactosylceramide)
with an AGFA desktop scanner; HPTLC semiquantitative analysis wasare also elevated in NPC disease [8, 10, 11], and of these,
done with NIH Imaging 1.62. GM3 and GM2 levels fell within a linear
lactosylceramide remained equivalent to NPC-affected range when compared to a calibration curve determined by a scan of
brain in the double mutant mice. It is therefore likely known quantities of GM1 ganglioside. Immunocytochemical methods
used in these studies were carried out as previously reported [9].that the treatment of NPC disease with NB-DNJ in our
study is beneficial because it diminishes glycosphingo-
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